8-K 1 f8-k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8‑K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 23, 2018

GlycoMimetics, Inc.

(Exact name of registrant as specified in its charter)

Delaware |  | 001-36177 |  | 06-1686563
(State or other jurisdiction of incorporation) |  | (Commission File Number) |  | (IRS Employer Identification No.)

9708 Medical Center Drive

Rockville, MD 20850

(Address of principal executive offices, including zip code)

(240) 243-1201

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indícate by check mark whether the registrant is an emerging growth Company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b‑2 of the Securities Exchange Act of 1934 (§240.12b‑2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☑

Item 7.01 Regulation FD Disclosure.

On July 23, 2018, GlycoMimetics, Inc. (the “Registrant”) was notified by its collaborator Pfizer Inc., the company responsible for ongoing clinical development of the Registrant’s drug candidate rivipansel, that the ongoing Phase 3 trial with rivipansel is approximately 75% enrolled and that Pfizer now expects to complete enrollment in early 2019 and to have top line data available in the second quarter of 2019. Pfizer had previously announced its expectation to complete enrollment in the second half of 2018 and to have preliminary results available by the end of 2018.

The Registrant has updated its corporate presentation accordingly. A copy of the updated presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is also available on the Registrant’s website at http://ir.glycomimetics.com/investor-relations.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit |  |
Number |  | Exhibit Description
99.1 |  | GlycoMimetics Corporate Presentation, dated July 2018.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|  | GLYCOMIMETICS, INC.
| By: | /s/ Rachel K. King
Date: July 25, 2018 |  | Rachel K. King Chief Executive Officer

3